KDR and neoplasm: Based on these results, we elected to compare two of the FDA-approved agents in our preclinical PDX tumor models: Lenvatinib as a potentially efficacious dual FGFR/VEGFR therapeutic and Sunitinib as a VEGFR inhibitor control with modest effects on fish melanogenesis.